

K083927

1062

**510(k) Summary of Safety
and Effectiveness Information**

**Regulatory
Authority:**

Safe Medical Devices Act of 1990,
21 CFR 807.92

Company:

Biolase Technology, Inc.
4 Cromwell
Irvine, CA 92618

OCT - 1 2009

Contact:

Ms. Ioana M. Rizoiu
Biolase Technology, Inc.
4 Cromwell
Irvine, CA 92618
Tel: (949) 226-8144
Fax: (949) 273-6680

Trade Name:

Waterlase® MD

Common Name:

Er,Cr:YSGG laser

Classification Name:

Surgical laser instrument

Classification Code:

79 GEX, a Class II device

Equivalent Devices:

Millenium Dental Technologies, Inc
Fotona d.d.
Cynosure, Inc.

Periolase
Fidelis III Laser System Family
Smart CO2

Device Description:

The *Waterlase® MD* is a dental laser device previously cleared by the FDA (K031140) for hard and soft tissue dental indications, including periodontal procedures such as: *laser* soft tissue curettage, *laser* removal of diseased, infected, inflamed and necrosed soft tissue within the periodontal pocket, *removal* of highly inflamed edematous tissue affected by bacteria penetration of the pocket lining and junctional epithelium, *removal* of granulation tissue from bony defects, *sulcular* debridement (removal of diseased, infected, inflamed or necrosed soft tissue in the periodontal pocket to improve clinical indices including gingival index, gingival bleeding index, probe depth, attachment loss and tooth mobility), *osteoplasty* and *osseous* recontouring (removal of bone to correct osseous defects and create physiologic osseous contours), *ostectomy* (resection of bone to restore bony architecture, resection of bone for grafting, etc.), *osseous* crown lengthening, *full* thickness flap, *partial* thickness flap, and *split* thickness flap.

K083927

The **Waterlase®MD** is capable of soft tissue incision, excision, vaporization, ablation and coagulation. In the periodontal pocket, the **Waterlase®MD** is an effective laser for removing diseased/inflamed tissue, and the diseased epithelium lining from underlying connective tissues.

A flexible fiber optic terminated into the handpiece delivers the **Waterlase®MD** laser energy to the end fiber tip and target. A visible aiming light emitted from the handpiece's distal end pinpoints the area of treatment. Three fiber optic ports provide illumination from the handpiece to the tissue site in addition to the center beam emitting source. In both hard and soft tissue applications the power output, pulse duration, repetition rate (frequency) and air and water flow rates are adjustable to specific user requirements. The spot size and spot geometry can also be varied by changing tips which include different diameters and end configurations.

Indications for Use:

Waterlase MD Er,Cr:YSGG assisted new attachment procedure (cementum-mediated periodontal ligament new-attachment to the root surface in the absence of long junctional epithelium)

Contraindications:

All clinical procedures performed with **Waterlase®MD** must be subject to the same clinical judgment and care as with traditional techniques. Patient risk must always be considered and fully understood before clinical treatment. The clinician must completely understand the patient's medical history prior to treatment. Exercise caution for general medical conditions, which might contraindicate a local procedure. Such conditions may include, but are not limited to, allergy to local or topical anesthetics, heart disease, lung disease, bleeding disorders, sleep apnea or an immune system deficiency. Medical clearance from patient's physician is advisable when doubt exists regarding treatment.

Conclusion:

The indication included herein is the same as the indication that has been previously cleared by the FDA for other dental laser devices. Substantial equivalency for the **Waterlase®MD** has been determined through comparison to previously cleared dental laser devices.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room - WO66-0609
Silver Spring, MD 20993-0002

OCT - 1 2009

Ms. Ioana Rizoiu
Vice President of Clinical Research and Development
Biolase Technology, Incorporated
4 Cromwell
Irvine, California 92618

Re: K083927
Trade/Device Name: Waterlase® MD
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser Surgical Instrument for Use In General and Plastic Surgery
and In Dermatology
Regulatory Class: II
Product Code: GEX
Dated: September 25, 2009
Received: September 28, 2009

Dear Ms. Rizoiu:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/cdrh/mdr/> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Susan Runner, D.D.S., M.A.
Acting Division Director
Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

K083927

Indications for Use Statement

510(k) Number: K _____

Device (Trade) Name: *Waterlase*[®] MD

Indications for Use:

Waterlase MD Er,Cr:YSGG assisted new attachment procedure (cementum-mediated periodontal ligament new-attachment to the root surface in the absence of long junctional epithelium).

Prescription Use
 (Part 21 CFR 801 Subpart D)

AND/OR

Over-the-Counter Use _____
 (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Rai Hulyar Sr MSR
(Division Sign-Off)
Division of Anesthesiology, General Hospital
Infection Control, Dental Devices

510(k) Number: K083927